CytomX Therapeutics Inc. (NASDAQ:CTMX) shares traded down 0.9% on Monday . The company traded as low as $10.50 and last traded at $10.61, with a volume of 54,141 shares trading hands. The stock had previously closed at $10.71.

A number of research analysts have weighed in on the company. Jefferies Group restated a “buy” rating and issued a $19.00 price objective on shares of CytomX Therapeutics in a report on Wednesday, March 16th. Zacks Investment Research raised CytomX Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, May 10th. Finally, Oppenheimer Holdings Inc. reissued a “buy” rating on shares of CytomX Therapeutics in a research report on Tuesday, May 10th. One equities research analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. CytomX Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $19.00.

The firm’s 50-day moving average is $10.08 and its 200-day moving average is $12.98. The stock’s market capitalization is $382.88 million.

CytomX Therapeutics (NASDAQ:CTMX) last issued its earnings results on Friday, May 6th. The company reported ($0.44) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.26) by $0.18. On average, analysts anticipate that CytomX Therapeutics Inc. will post ($1.40) earnings per share for the current year.

In other CytomX Therapeutics news, Director Timothy M. Shannon sold 51,343 shares of the firm’s stock in a transaction that occurred on Thursday, May 26th. The shares were sold at an average price of $10.34, for a total transaction of $530,886.62. Following the completion of the sale, the director now directly owns 134 shares in the company, valued at $1,385.56. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Ix L.P. Canaan sold 8,687 shares of the firm’s stock in a transaction that occurred on Friday, May 20th. The stock was sold at an average price of $10.10, for a total transaction of $87,738.70. The disclosure for this sale can be found here.

An institutional investor recently bought a new position in CytomX Therapeutics stock. Casdin Capital LLC acquired a new position in shares of CytomX Therapeutics Inc. (NASDAQ:CTMX) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 321,023 shares of the company’s stock, valued at approximately $6,700,000. CytomX Therapeutics accounts for about 5.9% of Casdin Capital LLC’s investment portfolio, making the stock its 6th largest position. Casdin Capital LLC owned about 0.89% of CytomX Therapeutics at the end of the most recent reporting period.

CytomX Therapeutics, Inc is an oncology-focused biopharmaceutical company. The Company is engaged in the development of a class of antibody therapeutics based on its Probody technology platform. It uses its platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against a range of targets.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.